Latest Revenue Growth News

Atlas Arteria has received an unsolicited takeover offer from IFM Investors valuing the company at A$4.75 per security, a modest premium to recent prices. The board advises securityholders to take no immediate action as conditions and approvals remain uncertain.

Resmed delivered a robust Q3 FY2026 with 11% revenue growth, margin expansion, and a 21% jump in non-GAAP EPS, while announcing a new U.S. distribution centre and a $0.60 dividend.

FBR Limited secured its first overseas Mantis welding robot sale, launched the Firehawk refractory robot, and expanded its Wall as a Service footprint in Victoria, while navigating a cash balance under $700,000.

ReNerve Limited reports a 79% jump in quarterly sales, secures key Asia-Pacific approvals, and progresses its nerve repair pipeline with the NervAlign Nerve Guide Matrix entering Stage 3 development.

IMEXHS Limited kicked off FY26 with a 13% revenue increase and a strategic pivot to an AI-native radiology workflow platform, securing major contracts in Latin America and advancing proprietary AI agents.

Zimi Limited posted 14% revenue growth and landed its biggest project order to date with Homecorp, while slashing operating costs and launching an AI sales agent.

Little Green Pharma (ASX:LGP) posted record quarterly and annual revenues driven by a surge in European sales, improved cashflow, and reduced debt. The company is on track to complete its merger with Cannatrek by June 1, 2026, while benefiting from the US rescheduling of medicinal cannabis to Schedule III.

Beonic Limited’s Q3 FY26 results highlight a tripling of EBITDA margin to 15.8%, driven by operational leverage and gross margin expansion, while the Moroccan Airports rollout stays on track for full delivery by June 2026.

Pointerra Limited delivered a 214% jump in Q3 FY26 customer receipts to A$2.2 million, driven by milestone invoicing and new Tier 1 utility contracts, edging closer to operating cashflow breakeven.

Eden Innovations has expanded its EdenCrete Pz7 installations across North America, launched a new defence-focused division EdenShield, and eliminated costly debt, positioning for growth with a $4 million capital raise.

Regis Healthcare expects FY26 underlying EBITDA of approximately $135 million, buoyed by near-record occupancy and a disciplined capital strategy amid evolving government reforms.

Artrya has fully integrated its Salix platform at Tanner Health, is preparing two more US sites for launch, and is finalising FDA submission for its Coronary Flow module, backed by a strong cash position of $76.6 million.